List of works - Kazuo Umezawa

A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ.

scientific article

A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice ⬇️

scientific article published on September 21, 2011

AMPK-NF-κB axis in the photoreceptor disorder during retinal inflammation

scientific article

Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy

scientific article

Activation of Akt involves resistance to NF-κB inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells

scientific article published on 13 November 2013

Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats

scientific article published on 12 April 2016

Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration

scientific article published on 23 June 2020

Antineoplastic effects of NF-κB inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) alone and in co-treatment with radio-and chemotherapy in medulloblastoma cell lines

scientific article published on 13 November 2017

Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells

scientific article published on December 2003

Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells

scientific article published on 04 May 2020

BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation

scientific article published on 07 September 2006

Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma

scientific article published on May 2006

Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma

scientific article published on 5 November 2009

Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells

scientific article published on January 2013

Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy

scientific article

Corrigendum to "poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells" [Biochim. Biophys. Acta 1853(12)(2015) 3224-3234]

scientific article published on 21 April 2018

DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts

scientific article

Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a stratum corneum-removed murine model through NF-κB inhibition

scientific article published on 06 February 2019

Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.

scientific article published on 24 July 2008

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model

scientific article published on 12 August 2020

Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components

scientific article published on 01 September 2011

Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer

scientific article published on 29 April 2015

Effect of a novel nuclear factor-κB activation inhibitor on renal ischemia-reperfusion injury.

scientific article

Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis

scientific article published on 27 June 2016

Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage

scientific article published on September 2013

Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.

scientific article published in September 2013

Efficient Cellular Uptake of the Novel NF-κB Inhibitor (−)-DHMEQ and Irreversible Inhibition of NF-κB in Neoplastic Cells ⬇️

scientific article published on January 1, 2010

Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.

scientific article

Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes.

scientific article

Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.

scientific article

ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer

scientific article published on 5 April 2012

External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice

scientific article published in June 2017

Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway

scientific article published on 28 May 2019

Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.

scientific article

In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia

scientific article

Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues

scientific article

Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.

scientific article

Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.

scientific article

Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells

scientific article published on 22 September 2009

Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.

scientific article

Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.

scientific article

Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells

scientific article

Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis

scientific article published on 8 February 2017

Inhibition of NF-kappaB with Dehydroxymethylepoxyquinomicin modifies the function of human peritoneal mesothelial cells

scientific article published on 15 December 2016

Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells

scientific article published on January 2016

Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (−)-DHMEQ via activation of Nrf2–ARE pathway ⬇️

scientific article published on February 26, 2013

Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide

scientific article

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

scientific article

Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ.

scientific article

Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding

scientific article

Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow

scientific article published on 01 January 2005

Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin

scientific article published on 14 March 2020

Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome

scientific article published on 4 November 2013

Inhibition of tumor growth by NF-kappaB inhibitors

scientific article published on 22 August 2006

Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin

scientific article published on 30 April 2002

Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB

scientific article published on 06 March 2012

Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion

scientific article

JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells

scientific article published on 15 March 2019

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.

scientific article published on 9 November 2017

NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells

scientific article published on 07 October 2020

NF‑κB inhibitor DHMEQ inhibits titanium dioxide nanoparticle‑induced interleukin‑1β production: Inhibition of the PM2.5‑induced inflammation model

scientific article published on 03 October 2018

Novel approaches to target NF-κB and other signaling pathways in cancer stem cells

scientific article

Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction

scientific article published in April 2003

Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB

scientific article published on 01 January 2011

Pleiotropic Potential of Dehydroxymethylepoxyquinomicin for NF-κB Suppression via Reactive Oxygen Species and Unfolded Protein Response ⬇️

scientific article published on May 20, 2013

Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells

scientific article published on 26 July 2014

Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.

scientific article published on 13 February 2010

Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.

scientific article published in August 2005

Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor

scientific article published on 8 December 2016

Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin

scientific article published on 24 May 2010

Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy

scientific article

Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

scientific article

Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.

scientific article published on April 2006

Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells

scientific article published on January 2012

The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

scientific article published on 2 April 2014

The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome

scientific article published on April 2013

The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal Inflammation

scientific article published on 15 January 2016

The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats

scientific article published on 06 August 2008

The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.

scientific article

Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models

scientific article published on 16 December 2017

Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition

scientific article published on August 2010

Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.

scientific article

Treatment with novel AP-1 and NF-κB inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis

scientific article published on 5 February 2016

List of works by Kazuo Umezawa

A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ.

A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice ⬇️

AMPK-NF-κB axis in the photoreceptor disorder during retinal inflammation

Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy

Activation of Akt involves resistance to NF-κB inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells

Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats

Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration

Antineoplastic effects of NF-κB inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) alone and in co-treatment with radio-and chemotherapy in medulloblastoma cell lines

Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells

Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells

BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation

Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma

Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma

Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells

Conophylline protects cells in cellular models of neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy

Corrigendum to "poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells" [Biochim. Biophys. Acta 1853(12)(2015) 3224-3234]

DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts

Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a stratum corneum-removed murine model through NF-κB inhibition

Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model

Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components

Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer

Effect of a novel nuclear factor-κB activation inhibitor on renal ischemia-reperfusion injury.

Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis

Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage

Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.

Efficient Cellular Uptake of the Novel NF-κB Inhibitor (−)-DHMEQ and Irreversible Inhibition of NF-κB in Neoplastic Cells ⬇️

Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.

Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes.

Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.

ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer

External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice

Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway

Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.

In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia

Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues

Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.

Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.

Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells

Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.

Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.

Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells

Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis

Inhibition of NF-kappaB with Dehydroxymethylepoxyquinomicin modifies the function of human peritoneal mesothelial cells

Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells

Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (−)-DHMEQ via activation of Nrf2–ARE pathway ⬇️

Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ.

Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding

Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow

Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin

Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome

Inhibition of tumor growth by NF-kappaB inhibitors

Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin

Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB

Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion

JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.

NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells

NF‑κB inhibitor DHMEQ inhibits titanium dioxide nanoparticle‑induced interleukin‑1β production: Inhibition of the PM2.5‑induced inflammation model

Novel approaches to target NF-κB and other signaling pathways in cancer stem cells

Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction

Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB

Pleiotropic Potential of Dehydroxymethylepoxyquinomicin for NF-κB Suppression via Reactive Oxygen Species and Unfolded Protein Response ⬇️

Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells

Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.

Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.

Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor

Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin

Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy

Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.

Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells

The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.

The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome

The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal Inflammation

The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats

The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.